SCHEDULE: Leviticus Partners Boosts Harvard Bioscience Stake

Leviticus Partners LP and AMH Equity LLC have increased their beneficial ownership in Harvard Bioscience Inc. to 9.2% of common stock.

Summary

• Leviticus Partners LP and AMH Equity LLC, both managed by Adam M Hutt, reported beneficial ownership of 4,047,535 shares of Harvard Bioscience Inc. common stock.
• This ownership represents 9.2% of the company's common stock outstanding.
• The filing is an Amendment No. 4 to a Schedule 13G, filed under Rule 13d-1(c).
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: Neutral. A Schedule 13G filing is a routine disclosure of passive ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. The filing explicitly states the shares are held in the ordinary course of business and not for control purposes, though it allows for director nominations under specific rules.

Future Outlook

NA

Industry Context

This filing indicates increased institutional interest in Harvard Bioscience, a company operating in the life sciences and biotechnology tools sector. Such disclosures are common for passive investors accumulating stakes.

Stakeholder Impact

• Increased institutional ownership may signal confidence to other investors.
• No direct operational impact on employees, customers, or suppliers is indicated by this filing.

Key Dates

Keywords

Harvard Bioscience, Leviticus Partners, AMH Equity, Adam M Hutt, Common Stock, Beneficial Ownership, Schedule 13G, Institutional Investor, Biotechnology, Life Sciences